Indicated for attention deficit hyperactivity disorder to manage focus levels and support behavioral regulation.
Mechanism of Action
Atomoxetine selectively inhibits the presynaptic norepinephrine transporter in the prefrontal cortex, increasing synaptic concentrations of norepinephrine to improve attention and reduce hyperactivity.
Route of Administration
Oral
Onset Time
1–4 weeks
Duration
24 hours
Contraindications
Narrow-angle glaucoma, Pheochromocytoma, Concurrent use of MAO inhibitors, Severe cardiovascular disease
Severe Adverse Events
Suicidal ideation, Hepatotoxicity, Priapism — requires immediate medical attention
Common Side Effects
Decreased appetite, Nausea, Dry mouth
Uncommon Side Effects
Somnolence, Insomnia, Abdominal pain
Drug Interactions
Alcohol, MAO Inhibitors, Fluoxetine, Albuterol, Paroxetine
Pregnancy Safety Warnings
FDA Category C: Use only if clearly needed. Breastfeeding: Excretion in milk is unknown; use with caution.
Age Restrictions
Safety and efficacy established in pediatric patients six years and older.
Information related to Strattera is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
